Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.
about
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancersMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibSomatic mutations of the epidermal growth factor receptor and non-small-cell lung cancerMutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasIdentifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancerMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularRole of molecular studies in the diagnosis of lung adenocarcinomaAssociation of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Benchmarking of mutation diagnostics in clinical lung cancer specimensPrognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 studyMorphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.Snapback primer mediated clamping PCR for detection of EGFR and KRAS mutations in NSCLC patients by high resolution melting analysisEGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection.EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinomaA pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinomaMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularPhase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.Small-cell lung cancers in patients who never smoked cigarettes.A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistryIdentification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies.Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenibRelationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer.Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancerRebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype.Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR geneDetection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
P2860
Q24611043-66C8F445-C621-451D-9253-B931612E1621Q24646295-726A913C-8BF4-4D27-A2AE-123E8FBEF0B4Q24648133-9430E30F-6C5A-4888-8AF2-C96DAECB3F72Q24669579-714C9A9C-2C1C-499A-AAB4-D39589587D06Q26781810-A38C2527-4693-4E1E-83E2-9030E556B851Q26828860-4124F8E6-F704-4C2B-B8C0-504407578ECDQ27023212-40588529-D02F-4D3A-AE79-EEA3396F713AQ27851860-AFC5BFCC-BB8A-42AB-A858-A606A44C8A2FQ27852116-4CA51C10-F90B-4799-BD4A-8D247E7DE818Q28740430-405419FE-ACCA-43CD-97A2-B67A87973835Q30498101-10BDAFC5-97C3-4EE5-8C6B-379E1EE1FA38Q30544631-13A52BFE-BAE4-42E6-A8AB-CCEE43C1E598Q33594324-6C5F5C82-ACB7-49DB-97E3-381B3378C851Q33634383-FD254EBC-F952-4661-B4B0-DBB7A8B30492Q34096414-A30A4D69-517C-48A5-8F21-9BED00293957Q34108365-F95481AC-3D05-49E4-AB25-45DA74169E06Q34134408-306EE1BD-D06F-43EA-AA03-A5C0AD998AE8Q34158952-66C686D2-D770-4B79-8A28-EF7B478A5203Q34158993-28C03E68-7B4A-4CDF-AE5E-FF59B88F3C12Q34159011-3AC63B92-54BF-4320-92C7-1525854CB7CBQ34314653-36603CD6-C41A-4ABD-93DE-94614CA3A31BQ34352284-50B6CF60-2290-4321-8D92-3BAAFF8CEFBBQ34405695-2B8626D0-46D4-4370-B000-A12B93EDA507Q34522899-6317375B-A42F-47B8-A23F-6033F0D2ACA2Q34570834-DD6C0680-3D35-450A-80F6-D59CB5E85CDFQ34610381-3833EDF4-FD93-43D6-B789-520CD84A4CE4Q34625305-83A78FCA-E87E-422A-8CC6-3103049C9C34Q34637846-FBE5F97B-8105-46E8-9360-EFD865899390Q34694358-EDEE1910-F403-4BD5-8C65-24885D3EF669Q34760642-631F0B7D-567B-4D70-AA8D-252198097734Q34762839-0A788F5F-699F-422E-B95F-AF170ED806B9Q35023498-0DD88E88-82CD-45B2-B6E0-621A09104220Q35025931-3D482B1E-CDE5-4B71-A566-8C1065E48DE2Q35219157-BE54F506-A12A-470D-BF86-E12AA6AD22BFQ35551048-7F1D47BD-25A3-4B3E-B0E1-0011ECBED445Q35570245-5675ACC8-0E36-47C4-B4AD-C400297F0592Q35592279-0FFDCFCA-62A8-46B1-8553-224D5E65455AQ35604575-1C93E054-A549-4414-A9C5-4F9813334282Q35681816-668A6E49-B953-4B38-9E8E-4F86964831BBQ35764712-21C7BE78-6DD8-4EFB-B14F-EAFA9EB0FDD5
P2860
Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Rapid polymerase chain reactio ...... tions in lung adenocarcinomas.
@ast
Rapid polymerase chain reactio ...... tions in lung adenocarcinomas.
@en
type
label
Rapid polymerase chain reactio ...... tions in lung adenocarcinomas.
@ast
Rapid polymerase chain reactio ...... tions in lung adenocarcinomas.
@en
prefLabel
Rapid polymerase chain reactio ...... tions in lung adenocarcinomas.
@ast
Rapid polymerase chain reactio ...... tions in lung adenocarcinomas.
@en
P2860
P1476
Rapid polymerase chain reactio ...... tions in lung adenocarcinomas.
@en
P2093
P2860
P304
P356
10.1016/S1525-1578(10)60569-7
P577
2005-08-01T00:00:00Z